

Title:
Factors influencing mortality trends of pancreatic cancer in Spain, 1955-2020

Authors:
Enrique Gili Ortiz

DOI: 10.17235/reed.2022.8559/2021

Link: [PubMed \(Epub ahead of print\)](#)

Please cite this article as:

Gili Ortiz Enrique. Factors influencing mortality trends of pancreatic cancer in Spain, 1955-2020. Rev Esp Enferm Dig 2022. doi: 10.17235/reed.2022.8559/2021.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Factors influencing mortality trends of pancreatic cancer in Spain, 1955-2020

Short title: Mortality trends of pancreatic cancer in Spain

Author: Enrique Gili-Ortiz. MD.

Correspondence:

Servicio de Anestesiología y Reanimación

Hospital Can Misses

c/Corona s/n, 07800-Ibiza,

Balearic Islands, Spain.

T. 637721333

egiliort@gmail.com

Abstract

Objectives: The aim of this study is to analyse the trends of pancreatic cancer mortality in Spain during the period 1955-2020 in both genders and every age group, trying to describe the changes in the prevalence of some risk factors and their possible influence on mortality.

Methods: Direct standardized mortality rates were calculated using the World Standard Population 2000-2025 and Joinpoint analysis was performed for age-specific and age-standardized mortality trends for the period 1955-2020.

Results: Mortality rates increased with age in both genders, with a marked increase in older groups. During 2020, 71.5% of male deaths and 81.5% of female deaths by pancreatic cancer occurred among those aged 65 years or more. Spanish National Health Surveys since 1987 show decreasing trends in daily smoking, but striking increases in obesity and diabetes mellitus rates in both genders, and rates of daily smoking and obesity are remarkably higher among disadvantaged social classes.

Conclusions: Pancreatic cancer mortality rates have increased uninterruptedly in Spain during the last decades. Increasing trends in obesity and diabetes mellitus, particularly among males, and the different prevalence of obesity and smoking according to social class are public health problems of great concern. Smoking and obesity are potentially avoidable risk factors, so, educational programs

and legislative measures should be implemented more widely, such as programs of eradication of smoking, healthy nutrition and physical exercise, and would be applied more intensively in the most disadvantaged social classes.

Key words: Pancreatic cancer. Trends. Incidence. Mortality. Spain. Risk factors.

INTRODUCTION

Pancreatic cancer caused 496,000 new cases and 466,000 deaths in the world in 2019 (2.6% of all new cases of cancer and 4.7% of all cancer deaths) and was the seventh leading cause of cancer death in both genders (1). It has been estimated that in Spain in 2021 there will be 4,571 new cases among men (2.88% of all new cases of cancer among men) and 4,126 new cases among women (3.52% of all new cases of cancer among women), with low five-year survival rates worldwide (rates in Spain of 6.7% in men and 9.6% in women) (2).

Risk factors for pancreatic cancer are largely unknown but major risk factors for developing pancreatic cancer include family history (3, 4, 5), obesity (6, 7, 8, 9, 10), type 2 diabetes (5, 8, 11), smoking (5, 6, 12, 13) and age (14, 15). Other risk factors are chronic pancreatitis and some gene mutations (5, 6, 14). Some studies show that appropriate consumption of fresh fruit and vegetables may protect against pancreatic cancer (16).

Globally, the worldwide number of deaths and incident cases caused by pancreatic cancer has more than doubled from 1990 to 2017 (15), and in some countries it is projected to become the second-leading cause of cancer-related mortality by 2030 (6, 17).

These increasing incidence trends are attributed to remarkable changes in the prevalence of the aforementioned risk factors in developed countries, as aging of population and increasing rates of obesity and diabetes mellitus (DM) (18, 19). During the last decades there have been notable changes in the prevalence of these risk factors in Spain, first with an increase in the prevalence rate of smokers, and later a decrease in tobacco consumption, but also with striking increases in the prevalence of obesity and DM, all this together with a progressive aging of the population (20). The aim of this study is to analyse the trends of pancreatic cancer mortality in Spain during the period 1955-2020 in both genders and every age group, trying to describe the changes in the prevalence of some risk factors and their possible influence on mortality, in an attempt to identify the most

appropriate measures to reduce the frequency and lethality of this tumour.

MATERIAL AND METHODS

Spanish population and mortality data were retrieved from the Spanish National Statistics Institute (“Instituto Nacional de Estadística”, INE) online public databases (21). The code used for the period 1955-1998 was 157 (7th, 8th and 9th Revision of the International Classification of Diseases (ICD7, ICD8 and ICD9) and code for the period 1999-2020 was C25 (10th Revision of the International Classification of Diseases (ICD10)).

Mortality and resident population data for males and females were stratified yearly by 18 five-year age groups (from 0-4 years to 85 years or more). Total and sex-specific death rates for each quinquennial age group were computed for every calendar year and expressed as rates per 100,000 persons-years.

All ages-standardized mortality rates and truncated at 30-84 years per 100,000 persons-years were computed using the direct method and the WHO World Standard Population 2000-2025. 3-year moving averages were used to plot the age standardized mortality rates.

Joinpoint regression models were used for trend analysis (allowing up to three joinpoints), to identify significant changes in the linear slope (on a log scale) of age-standardized mortality rates and truncated standardized mortality rates over the period 1955-2020 (22). Annual percent change (APC) was estimated for each trend segment identified by the model and Average annual percent change (AAPC) was estimated for the whole period (23). Increases or declines were considered to occur when the slope of the trend was found to be statistically different from zero (two-tailed $p < .05$).

Results of National Health Surveys (NHS) from 1987, 1993, 1995, 1997, 2001, 2003, 2006, 2011, 2014 and 2017 were obtained from Spanish Ministry of Health, Consumption and Social Welfare (24). Data of daily smoking prevalence by age and gender, and obesity (defined as Body Mass Index (BMI) ≥ 30.0 kg/m²), and its distribution by social class were also obtained from NHS Ministry’s public databases.

The Ministry uses a classification of Social Class for their National Health Surveys, where Social Class I: Directors and managers of establishments with 10 or more employees and professionals traditionally associated with university degrees, and Social Class VI: Unskilled workers. In this study a comparison was made between Social Class I (higher) and Social Class VI (lowest) for two risk

factors: obesity and daily smoking by age and gender in every NHS where this information was available.

The joinpoint analysis was performed with Joinpoint Regression Program 4.9.0.0 (obtained from the Surveillance Research Program, National Cancer Institute). The handling of data, graphics and additional statistical analyses were performed with the STATA MP 14 software program.

RESULTS

Pancreatic cancer age-standardized mortality rates in males increased from 1.24 per 100,000 person-years in 1955 to 8.27 per 100,000 person-years in 2020, and among females from 1.29 per 100,000 person-years in 1955 to 5.68 per 100,000 person-years in 2020 (Figure 1). The mortality males: females ratio evolved from 0.74 in 1955 to 1.01 in 2020.

Mortality rates increased with age in both genders, with a marked increase in older groups, as depicted in Figure 2. During 2020, 71.5% of male deaths and 81.5% of female deaths by pancreatic cancer occurred among those aged 65 years or more. The results suggest that mortality trends have softened in recent decades, particularly among those under 50 years of age.

Joinpoint analysis for age-specific and age-standardized mortality rates is shown in Table 1. In males, there was an overall increase in the rates of 3% per annum. Joinpoint analysis detected two change points (1962 and 1988): during the first period (1955-1962) rates increased by 11.07% annually, during the second period (1962-1988) 3.61% and by 0.88% during the third period (1988-2020). In females, there was an overall increase in the rates of 2.6% annually, and joinpoint analysis detected two change points also (1963 and 1990), generating three periods: 1955-1963 (7.5% annually), 1963-1990 (2.43% annually) and 1990-2020 (1.42% annually).

Among males, age-specific mortality rates increased in all age-groups (30-34 years old to 85 or more years old), with AAPC of 2.0% or more from men aged 35-39 to AAPC of 3.9% among those aged 85 or more. Joinpoint analysis shows a statistically significant decrease in APCs among males aged 35-44 from the 90s, but not among females.

Among females, age-specific mortality rates also increased in all age-groups, but AAPCs were lower than among males and AAPC of 2.0% or more began at 50-54 years of age. All-ages standardized mortality rates and truncated standardized mortality rates increased among males and females but with lower AAPCs among females.

Results of NHS about daily smokers are exposed in Table 2. Results of 10 health surveys, from 1987 to 2017, show the prevalence of daily smokers by age and gender. Prevalence of daily smokers decreased in both genders, but with different slopes: declining steadily in males, but first increasing and later decreasing among females. Results show that decrease rate among males during the period 1987-2017 was 52.5% but among females it was 13.7%.

Results of NHS about obesity are depicted in Figure 3, showing notable increases in the prevalence of obesity in both genders during the period 1993-2017.

In the 1987 NHS, 3.12% of men and 4.74% of women said they had DM. In the following NHS, the prevalence rates increased progressively, and in 2017 the rates were 10.65% in men and 9.11% in women, that is, the prevalence of DM had tripled in men and doubled in women compared to 1987. According to the results of the NHS, the trends in obesity and daily smoking prevalence rates showed striking differences in both genders and in all age groups according to social class, being much higher among social class VI (Table 3).

DISCUSSION

Mortality rates from pancreatic cancer increased in Spain during the period 1955-2020 in both genders. This rise is attributable to progressive aging of the population, and increasing rates of tobacco smoking, obesity and DM. The role of chronic pancreatitis in these trends is probably much smaller, as the cumulative risk of pancreatic cancer among those with chronic pancreatitis is 1.8% after 10 years and 4% at 20 years (25).

The slower increase in pancreatic cancer mortality rates in the period 1988-2020 in males (APC 0.88%) and 1989-2020 in females (APC 1.42%) could be caused by the decline in tobacco consumption. In Spain, prevalence of daily smoking among males steadily decreased since the 80s while in females it rose until the late 90s and then decreased, and these differences could explain their different AAPCs (0.88% vs 1.42%). These different trends may explain also the negative trends in APC from late 90s to 2020 among males aged <50 years, not found among females. Among older people the impact of decline in smoking prevalence was not so marked, probably due to its cumulative effects during decades of heavy consumption.

The trends in obesity and DM prevalence rates in both sexes and in all age groups in Spain probably explain its upward trends despite the decline in tobacco use. Otherwise, Individuals with the longest duration of obesity have the highest risk of pancreatic cancer, particularly among

individuals who were overweight at younger ages, so, efforts to prevent childhood and youth obesity seem essential (26, 27).

The accuracy of Spanish cancer death certificates has been studied, and deaths from cancer as a whole and leading cancer types as cancer of the pancreas are well certified (28). Moreover, it is unlikely that the change from ICD9 codes to ICD10 implemented in 1999 has had an impact on the reliability of Spanish mortality data, as the codes are very similar, and trends in the leading causes of death have not been greatly affected by the revisions in ICD10 (29).

Diagnostic procedures have improved dramatically from 1955 to the present day. For example, techniques like Computerized Tomography were not implemented until the late 1970s and did not spread to a majority of centres until the 1980s. Therefore, an underestimation of pancreatic cancer diagnosis in previous years cannot be ruled out.

The US Preventive Services Task Force found no evidence that screening for pancreatic cancer or treatment of screen-detected pancreatic cancer improves disease-specific morbidity or mortality, or all-cause mortality, and reaffirms previous recommendation against screening for pancreatic cancer in asymptomatic individuals (30, 31).

Though survival in pancreatic cancer is still disappointingly low, a moderate improvement (slightly higher in men) has been described in some countries in the last years, which could have slowed the increase in the mortality rates since the 90s (32). Multimodality therapy with effective surgery, chemotherapy, and radiation are generally necessary to optimize long-term outcomes. While advances in surgery have led to improved outcomes over in recent decades, the development of more effective systemic therapies based on improved molecular approaches will be necessary to make further strides in pancreatic cancer care (33). Multidisciplinary work teams need to be formed for the best use of existing resources in order to improve current results, focusing on early diagnosis, apply more refined surgical techniques, greater attention to perioperative and postoperative care and the application of novel chemotherapy and even radiotherapy treatment protocols (34). For example, recent randomized controlled trials are showing promising results with neoadjuvant chemotherapy with Folfirinox or Gemcitabine in borderline resectable tumors (33, 35). Social class is associated with the prevalence of daily smoking, and NHS show that the prevalence of daily smoking and obesity among male and female unqualified workers (Social Class VI) is remarkably higher than those among high-qualified professionals (Social Class I). Another frequent problem in the most disadvantaged social classes is the delay in attending healthcare services in

case of illness. So, the implementation of preventive measures aimed at reducing the incidence and mortality of pancreatic cancer should be offered with greater emphasis on the most disadvantaged social classes.

These results need to be interpreted with caution. This study is limited by its ecological nature and the assumption that the higher prevalence of these risk factors found in other studies is also high among Spanish patients with this disease. Our results attempt to help identify trends and generate etiological hypotheses, but do not provide any direct evidence on the role of specific exposures such as obesity, diabetes, smoking and social class.

However, these results highlight the need for epidemiologic research to elucidate the causes of the increase in the incidence and mortality of pancreatic cancer in Spain, as well as to reinforce strategies to improve the early diagnosis and treatment of this cancer, curb the epidemic of smoking and obesity and shift the Spanish population towards a healthier diet and more active lifestyles. Research on procedures for early diagnosis and promising treatments such as neoadjuvant chemotherapy are also priorities to improve the low survival rates of this disease.

Table 1. Table 1. Joinpoint analysis of trends in age-specific mortality rates, Age-standardized mortality rates (Age-std) and truncated age-standardized 30-84 years mortality rates (Trunc-std) of pancreatic cancer, Spain, by gender, 1955-2010. Annual average percent change (AAPC) and Annual percent change (APC).

Gender	Age group	Joinpoints	AAPC	APC Period 1	APC Period 2	APC Period 3
Males						
	30-34	0	0.43	1955-2020:0.43		
	35-39	2	2.2*	1955-1960:29.97*	1960-1990:2.22*	1990-2020: -1.83*
	40-44	2	2.0*	1955-1962:14.39*	1962-1996:2.62*	1996-2020: -2.21*

	45-49	2	2.5*	1955-1959:24.97*	1959-2001:2.47*	2001-2020: -1.51
	50-54	2	2.5*	1955-1963:9.75*	1963-1999:2.55*	1999-2020: -0.34
	55-59	2	2.9*	1955-1961:15.20*	1961-1995:2.78*	1995-2020:0.35
	60-64	2	3.0*	1955-1963:11.0*	1963-1990:2.93*	1990-2020:1.11*
	65-69	2	3.0*	1955-1962:10.77*	1962-1985:3.77*	1985-2020:1.10*
	70-74	2	3.3*	1955-1960:13.74*	1960-1984:4.19*	1984-2020:1.29*
	75-79	2	3.4*	1955-1968:8.74*	1968-1987:3.80*	1987-2020:1.08*
	80-84	1	3.1*	1955-1988:5.08*	1988-2020:1.01*	
	85+	1	3.9*	1955-1985:7.36*	1985-2020:1.02*	
	Age-std	2	3.0*	1955-1962:11.07*	1962-1988:3.61*	1988-2020:0.88*
	Trunc-std	2	3.0*	1955-1962:10.93*	1962-1988:3.50*	1988-2020:0.88*
Females						
	30-34	0	0.48	1955-2020:0.48		
	35-39	0	0.88*	1955-2020:0.88*		
	40-44	2	0.9	1955-1979: -1.01	1979-1994:5.30*	1994-2020:0.23
	45-49	0	1.84*	1955-2020:1.84*		
	50-54	1	2.2*	1955-1962:6.37	1962-2020:1.68*	
	55-59	1	2.4*	1955-1962:7.89*	1962-2020:1.81*	
	60-64	1	2.3*	1955-1963:7.79*	1963-2020:1.60	
	65-69	1	2.5*	1955-1965:6.60*	1965-2020:1.75*	
	70-74	2	3.0*	1955-1961:15.63*	1961-1987:2.45*	1987-2020:1.28*
	75-79	2	2.8*	1955-1969:6.43*	1969-1988:2.71*	1988-2020:1.29*
	80-84	1	2.8*	1955-1985:4.74*	1985-2020:1.24*	
	85+	1	3.1*	1955-1993:4.70*	1993-2020:0.96*	
	Age-std	2	2.6*	1955-1963:7.50*	1963-1990:2.43*	1990-2020:1.42*
	Trunc-std	2	2.5*	1955-1963:7.68*	1963-1989:2.25*	1989-2020:1.46*

*P< 0.05.

Table 2. Prevalence of daily smokers in Spain by age and gender. Results of NHS 1987 to 2017. Results exposed in percentage.

Gender	NHS	Age groups								
		15-24	25-34	35-44	45-54	55-64	65-74	75 or more	All	
Males										
	1987	55.22	66.04	59.52	55.98	48.33	36.78	27.89	53.87	
	1993	38.60	57.92	57.47	48.41	37.37	22.36	16.29	43.98	
	1995	38.95	56.01	52.31	45.08	40.88	30.14	14.20	43.50	
	1997	35.95	53.42	57.69	48.92	34.33	22.76	15.12	42.11	
	2001	36.48	48.05	52.02	43.43	35.57	19.46	13.42	39.21	
	2003	34.74	38.65	44.39	41.81	26.82	18.99	8.56	34.15	
	2006	24.96	40.16	37.41	38.83	28.45	18.64	8.93	31.56	
	2011	22.48	35.68	32.83	34.34	26.26	16.16	7.91	27.87	
	2014	21.43	35.09	32.74	33.57	28.56	16.38	8.24	27.57	
	2017	19.96	32.89	32.45	29.43	26.07	16.51	7.66	25.58	
Females										
	1987	48.44	44.82	21.11	6.33	3.16	1.85	1.55	21.75	
	1993	33.83	41.32	27.66	11.73	5.40	1.63	1.54	20.77	
	1995	40.54	46.94	32.40	14.19	7.27	2.10	0.48	24.51	
	1997	34.48	50.16	35.34	17.94	5.68	1.67	0.90	24.77	
	2001	36.92	40.32	39.55	22.76	8.18	2.45	0.56	24.65	
	2003	31.10	34.13	36.02	25.51	7.54	2.36	0.81	22.39	
	2006	28.93	30.16	30.73	28.47	11.77	3.86	1.37	21.51	
	2011	20.95	28.26	28.25	29.97	15.35	4.58	0.76	20.22	
	2014	15.46	24.84	24.52	26.42	20.82	6.74	1.24	18.60	
	2017	15.05	24.31	24.82	26.37	22.16	7.82	2.01	18.76	

Table 3. Obesity and daily smoking in Spain. Comparison between Social Class I and VI by age group and gender. Results of NHS from 2001 to 2017. Prevalence rates in percentage. Obesity and Social Class definitions in text.

Obesity								
Age group	Gender	Social Class	2001	2003	2006	2011	2014	2017
25-44	Males	I	5.93	10.01	12.17	7.85	9.74	8.56
		VI	16.73	14.70	12.65	15.43	14.31	14.41
	Females	I	3.29	1.72	2.93	4.22	3.05	4.0
		VI	9.76	15.77	15.67	16.05	21.12	19.19
45-64	Males	I	13.18	10.31	17.72	14.64	15.95	13.77
		VI	14.31	20.67	23.59	26.57	25.02	25.04
	Females	I	3.42	11.34	7.90	6.17	4.93	7.20
		VI	27.88	27.78	24.03	22.17	23.22	23.31
65 or more	Males	I	18.30	13.24	17.12	19.0	13.9	14.58
		VI	13.48	18.53	22.46	27.19	24.76	23.43
	Females	I	-	10.02	19.51	4.03	5.89	15.95
		VI	33.09	24.40	28.57	29.04	30.31	32.05
Daily smokers								
Age group	Gender	Social Class	2001	2003	2006	2011	2014	2017
25-44	Males	I	39.14	29.99	24.95	16.13	21.58	15.53

		VI	55.31	48.35	41.85	41.36	41.38	45.52
	Females	I	32.37	21.19	18.73	20.53	14.3	12.02
		VI	47.34	40.61	32.54	28.61	25.88	30.22
45-64	Males	I	38.88	25.18	20.1	22.98	18.99	15.6
		VI	49.69	38.42	38.2	37.46	37.13	30.81
	Females	I	36.64	27.88	25.71	26.63	22.16	16.03
		VI	16.12	13.13	22.3	24.61	26.47	25.81
65 or more	Males	I	11.7	12.54	11.61	14.05	15.3	11.39
		VI	18.95	16.15	14.58	11.08	14.25	15.49
	Females	I	-	11.78	14.13	10.33	10.4	11.09
		VI	2.82	0.47	1.57	1.37	2.42	4.2




Figure 1. Age-standardized mortality rates (ASMR) per 100,000, Spain, by gender, 1955-2020.




Figure 2. Age-specific mortality rates per 100,000, Spain, by gender, 1955-2020. (A: Males. B: Females).




Figure 3. Age-specific obesity rates by gender. Spanish NHS 1987-2017. (A: Males. B: Females).

REFERENCES

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; 71: 209-49.
2. Sociedad Española de Oncología Médica. Las cifras del cáncer en España: 2021. Madrid: SEOM.2021.
3. Jacobs EJ, Chanock SJ, Fuchs CS, et al. Family history of cancer and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). *Int J Cancer* 2010; 127: 1421-28.
4. Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. *Gastroenterology* 2013; 144: 1252-61.
5. Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer. *Lancet* 2020; 395: 2008-20.
6. Park W, Chawla A, O'Reilly EM. Pancreatic Cancer: A Review. *JAMA* 2021; 326: 851-62.
7. Li D, Morris JS, Liu J, et al. Body Mass Index and risk, age of onset, and survival in patients with pancreatic cancer. *JAMA* 2009; 301: 2553-62.
8. Stevens RJ, Roddam AW, Spencer EA, et al, on behalf of the Million Women Study Collaborators. Factors associated with incident and fatal pancreatic cancer in a cohort of middle-aged women. *Int J Cancer* 2009; 124: 2400-5.
9. Arslan AA, Helzlsouer KJ, Kooperberg C, et al. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). *Arch Intern Med* 2010; 170: 791-802.
10. Jacobs EJ, Newton CC, Patel AV, et al. The association between Body Mass Index and pancreatic cancer: variation by age at Body Mass Index assessment. *Am J Epidemiol* 2020; 189: 108-15.
11. Andersen DK, Korc M, Petersen GM, et al. Diabetes, pancreatogenic diabetes, and pancreatic cancer. *Diabetes* 2017; 66: 1103-10.
12. GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. *Lancet* 2017; 389: 1885-906.
13. McGuigan A, Kelly P, Turkington RC, et al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. *World J Gastroenterol* 2018; 24:

4846-61.

14. Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: Global trends, etiology and risk factors. *World J Oncol* 2019; 10: 10-27.
15. GBD 2017 Pancreatic Cancer Collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Gastroenterol Hepatol* 2019; 4: 934-47.
16. Zheng J, Guinter MA, Merchant AT, et al. Dietary patterns and risk of pancreatic cancer: a systematic review. *Nutr Rev* 2017; 75: 883-908.
17. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. *Cancer Res* 2014; 74: 2913-21.
18. NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. *Lancet* 2016; 387: 1377-96.
19. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. *Lancet* 2016; 387: 1513-30.
20. Gutiérrez-Fisac JL, Suárez M, Neira M, et al. Tendencia de los principales factores de riesgo de enfermedades crónicas. España, 2001-2011/12. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad, 2013.
21. INEbase/Sociedad-INE. Instituto Nacional de Estadística. (Accessed November 10, 2021) Available from: https://www.ine.es/dyngs/INEbase/es/categoria.htm?c=Estadistica_P&cid=1254735971047
22. Kim HJ, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates. *Stat Med* 2000; 19: 335-51 (correction: 2001; 20: 655).
23. Clegg LX, Hankey BF, Tiwari R, et al. Estimating average annual per cent change in trend analysis. *Stat Med* 2009; 28: 3670-82.
24. Ministerio de Sanidad, Consumo y Bienestar Social. Encuestas Nacionales de Salud. (Accessed November 10, 2021). Available from:

<https://www.sanidad.gob.es/estadEstudios/estadisticas/encuestaNacional/aniosAnteriores.htm>

25. Swaroop Vege S, Chari ST. Chronic pancreatitis. *N Engl J Med* 2022; 386: 869-78.
26. Stolzenberg-Solomon RZ, Schairer C, Moore S, et al. Lifetime adiposity and risk of pancreatic cancer in the NIH-AARP Diet and Health Study cohort. *Am J Clin Nutr* 2013; 98: 1057-65.
27. Genkinger JM, Kitahara CM, Bernstein L, et al. Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies. *Ann Oncol* 2015; 26: 2257-66.
28. Pérez-Gomez B, Aragonés N, Pollán M, et al. Accuracy of cancer death certificates in Spain: a summary of available information. *Gac Sanit* 2006; 20 (Supl 3): 42-51.
29. Salmerón D, Cirera L, Saez M, et al. Influence of the introduction of the ICD-10 on tendencies of mortality by causes (1980-2004). *Gac Sanit* 2009; 23: 144-6.
30. Lucas AL, Kastrinos F. Screening for pancreatic cancer. *JAMA* 2019; 322: 407-8.
31. Henrikson NB, Aiello Bowles EJ, Blasi PR, et al. Screening for pancreatic cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA* 2019; 322: 445-54.
32. Soreide K, Aagnes B, Moller B, et al. Epidemiology of pancreatic cancer in Norway: trends in incidence, basis of diagnosis and survival 1965-2007. *Scand J Gastroenterol* 2010; 45: 82-92.
33. Brown ZJ, Cloyd J. Surgery for pancreatic cancer: recent progress and future directions. *HepatoBiliary Surg Nutr* 2021; 10: 376-8.
34. Morales R, Cuadrado A, Noguera JF, et al. Evaluación multidisciplinaria y tratamiento multimodal del cáncer de páncreas reseado. Estudio Observacional. *Rev Esp Enferm Dig* 2011; 103: 5-12.
35. Müller PC, Frey MC, Ruzza CM, et al. Neoadjuvant chemotherapy in pancreatic cancer: an appraisal of the current high-level evidence. *Pharmacology* 2021; 106: 143-53.